Conventional Versus Hypofractionated Radiation in High Risk Prostate Patients

Official Title

A Phase II Randomized Control Trial of Conventional Versus Hypofractionated Radiation Regimen in Single Phase Using IMRT Technique and Long Term Androgen Suppression Therapy in High-risk Prostate Cancer Patients.


Hypofractionated regimen in high-risk prostate cancer will allow the investigators to deliver higher biological doses to targets in order to improve tumour control and with acceptable rectal toxicity compared to conventional fractionation.

Trial Description

Primary Outcome:

  • The rate of late rectal toxicities between hypofractionated versus conventional fractionated schedules in high risk prostate cancer patients
Secondary Outcome:
  • The biochemical control (freedom from PSA failure) rate
  • Disease free survival

View this trial on

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society